Vicente-Vicente Laura, Casanova Alfredo G, Hernández-Sánchez M Teresa, Prieto Marta, Martínez-Salgado Carlos, López-Hernández Francisco J, Cruz-González Ignacio, Morales Ana I
Toxicology Unit, University of Salamanca, 37007 Salamanca, Spain.
Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain.
J Clin Med. 2021 Oct 26;10(21):4942. doi: 10.3390/jcm10214942.
Contrast-induced nephropathy (CIN) is a complication associated with the administration of contrast media (CM). The CIN diagnosis is based on creatinine, a biomarker late and insensitive. The objective proposed was to evaluate the ability of novel biomarkers to detect patients susceptible to suffering CIN before CM administration. The study was carried out with patients undergoing cardiac catheterization involving CM. Patients were divided into two groups: (1) CIN, patients who developed this pathology; (2) control, patients who did not suffer CIN. Prior to the administration of CM, urine samples were collected to measure proteinuria, -acetyl-β-d-glucosaminidase, neutrophil gelatinase-associated lipocalin and kidney injury molecule-1, albumin, transferrin, t-gelsolin and GM2 ganglioside activator protein (GM2AP). The risk factors advanced age, low body mass index and low estimated glomerular filtration rate; and the urinary biomarkers albumin, transferrin and GM2AP showed significant predictive capacity. Of all of them, albuminuria demonstrated the highest diagnostic power. When a cutoff point was established for albuminuria at values still considered subclinical (10-30 µg/mg Cr), it was found that there was a high incidence of CIN (40-75%). Therefore, albuminuria could be applied as a new diagnostic tool to prevent and predict CIN with P4 medicine criteria, independently of risk factors and comorbidities.
对比剂肾病(CIN)是一种与使用对比剂(CM)相关的并发症。CIN的诊断基于肌酐,这是一种出现较晚且不敏感的生物标志物。本研究的目的是评估新型生物标志物在CM给药前检测易患CIN患者的能力。该研究针对接受涉及CM的心脏导管插入术的患者开展。患者被分为两组:(1)CIN组,即发生这种病变的患者;(2)对照组,即未患CIN的患者。在给予CM之前,收集尿液样本以测量蛋白尿、β-乙酰氨基葡萄糖苷酶、中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1、白蛋白、转铁蛋白、t-凝溶胶蛋白和GM2神经节苷脂激活蛋白(GM2AP)。高龄、低体重指数和低估计肾小球滤过率等危险因素,以及尿液生物标志物白蛋白、转铁蛋白和GM2AP显示出显著的预测能力。其中,蛋白尿的诊断能力最强。当将蛋白尿的临界值设定在仍被视为亚临床的值(10 - 30 µg/mg Cr)时,发现CIN的发生率很高(40 - 75%)。因此,蛋白尿可作为一种新的诊断工具,根据精准预防(P4)医学标准预防和预测CIN,而不受危险因素和合并症的影响。